Viridian Therapeutics, Inc.
VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the trā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.24
Price-4.71%
-$1.05
1Y
Price
Market Cap
$2.406b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-41794.0%
EBITDA Margin-44760.2%
Net Profit Margin-37545.8%
Free Cash Flow Margin-41794.0%
EBITDA Margin-44760.2%
Net Profit Margin-37545.8%
Free Cash Flow MarginRevenue
$71.127m
+0.4%
1y CAGR+7785.5%
3y CAGR+5818.6%
5y CAGREarnings
-$386.974m
-12.9%
1y CAGR-17.8%
3y CAGR-34.1%
5y CAGREPS
-$3.53
-6.3%
1y CAGR+11.8%
3y CAGR-0.1%
5y CAGRBook Value
$662.097m
$1.097b
Assets$435.136m
Liabilities$242.881m
DebtDebt to Assets
22.1%
-0.7x
Debt to EBITDAFree Cash Flow
-$335.039m
-21.0%
1y CAGR-21.9%
3y CAGR-40.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company